Nanomedicine is a novel and emerging field that has noted significant progress in both the fields of ophthalmology and cancer treatment. Expanding into ocular oncology, it holds the potential to overcome the limitations of conventional therapies, such as poor drug penetration due to anatomical and physiological ocular barriers and insufficient targeting, which can lead to collateral damage to healthy tissues. By reviewing a series of clinical and preclinical studies, we aim to outline the recent advancements, current trends and future perspectives in nanomedicine for ocular cancer treatment. Beyond improving the existing therapies, like chemotherapy, phototherapies and brachytherapy, nanomedicine enables multimodal applications by combining multiple treatments or integrating imaging for theranostic approaches. Additionally, it paves the way for experimental therapies, such as gene therapy, offering new possibilities for more effective and less invasive treatment strategies in ocular oncology.
纳米医学作为一个新兴领域，在眼科与癌症治疗方面均取得显著进展。在眼肿瘤学领域的拓展应用中，纳米医学有望突破传统疗法的局限性——例如因眼部解剖生理屏障导致的药物渗透性差、靶向性不足等问题，这些问题可能导致健康组织受到附带损伤。通过综述一系列临床与临床前研究，本文旨在系统阐述纳米医学在眼癌治疗领域的最新进展、当前趋势与未来前景。除优化化疗、光疗及近距离放射治疗等现有疗法外，纳米医学还能通过联合多种治疗手段或整合成像技术实现诊疗一体化应用。此外，该领域为基因治疗等实验性疗法开辟了新路径，为眼肿瘤学领域开发更高效、微创的治疗策略提供了全新可能。
肿瘤(癌症)患者之家